Norbert G Riedel
CIK 1161662 · EXECUTIVE CHAIRMAN OF THE BOD · last filed 2026-09-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BAX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3000 EL CAMINO REAL, 2 PALO ALTO SQUARE
PALO ALTO, CA 94306
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| JAZZ | Director | 19,245 | $206.69 | $3.98M | -$3.30M | 21 | 2026-09-02 |
| ETON | Director | 224,300 | $50.48 | $11.32M | $30.0K | 13 | 2026-08-04 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Director | 56,553 | $44.96 | $2.54M | $0 | 4 | 2024-06-07 |
| Aptinyx Inc. (APTX) Delisted | EXECUTIVE CHAIRMAN OF THE BOD | 650,265 | $0.06 | $39.7K | $366.4K | 13 | 2023-01-05 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Director | 28,540 | $18.07 | $515.7K | $0 | 2 | 2021-06-14 |
| ARIAD PHARMACEUTICALS INC (ARIA) Delisted | Director | 0 | $24.07 | $0 | $0 | 8 | 2017-02-16 |
| BAX | Corporate Vice President | 56,689 | $25.04 | $1.42M | -$25.15M | 17 | 2013-01-18 |
| OSCIENT PHARMACEUTICALS CORP (OSCI) Delisted | Director | 1,340 | — | — | $0 | 2 | 2008-06-13 |
Recent Filings · Page 3 of 9
86 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-08-14 | JAZZ | Notice (144) | −2,561 | -$346.2K | EDGAR |
| 2023-06-09 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Grant (A) | +3,282 | $0 | EDGAR |
| 2023-03-03 | ETON | Grant (A) | — | $0 | EDGAR |
| 2023-01-05 | Aptinyx Inc. (APTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-08-09 | JAZZ | Mixed | +1,472 | -$970.6K | EDGAR |
| 2022-06-16 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-02-28 | ETON | Grant (A) | — | $0 | EDGAR |
| 2022-01-06 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Exer (M) | +14,270 | $0 | EDGAR |
| 2021-12-08 | Aptinyx Inc. (APTX) Delisted | Buy (P) | +100,000 | $223.0K | EDGAR |
| 2021-12-07 | Aptinyx Inc. (APTX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.